The average of price targets set by Wall Street analysts indicates a potential upside of 40.5% in BioMarin (BMRN). While the effectiveness of this highly sought-after metric is questionable, the ...
Oppenheimer upgraded BioMarin (BMRN) to Outperform from Perform with a $98 price target BioMarin reported strong Q4 results and Oppenheimer ...
Oppenheimer upgraded BioMarin (BMRN) to Outperform from Perform with a $98 price target Discover the Best Stocks and Maximize Your Portfolio: ...
BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) had its target price upped by UBS Group from $109.00 to $113.00 in a ...
Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 9.6% in the pre-market session after the company ...
BioMarin Pharmaceutical BMRN reported fourth-quarter adjusted earnings per share of 92 cents, which beat the Zacks Consensus ...
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report)‘s stock had its “overweight” rating reissued by investment analysts ...
Q4 2024 Earnings Call Transcript February 19, 2025 BioMarin Pharmaceutical Inc. beats earnings expectations. Reported EPS is ...
BioMarin Pharmaceutical (NASDAQ: BMRN) was a lively stock in the best way on Thursday following the release of its latest set of quarterly results. Enthusiastic investors traded the company's ...